TABLE 1.
Characteristics of vHSIL patients treated with topical imiquimod therapy
| Patient number | Center | Age at start imiquimod | Response |
|---|---|---|---|
| 1 | LUMC | 52 | CR |
| 2 | LUMC | 42 | CR |
| 3 | LUMC | 52 | CR |
| 4 | LUMC | 31 | PR |
| 5 | LUMC | 36 | PR |
| 6 | LUMC | 30 | CR |
| 7 | LUMC | 53 | PR |
| 8 | LUMC | 55 | PR |
| 9 | LUMC | 46 | CR |
| 10 | LUMC | 45 | CR |
| 11 | LUMC | 60 | PR |
| 12 | LUMC | 49 | PR |
| 13 | LUMC | 70 | CR |
| 14 | LUMC | 58 | CR |
| 15 | LUMC | 69 | PR |
| 16 | LUMC | 58 | PR |
| 17 | LUMC | 37 | NR |
| 18 | HAGA | 34 | PR |
| 19 | HAGA | 56 | CR |
| 20 | HAGA | 50 | CR |
| 21 | HAGA | 51 | CR |
| 22 | HAGA | 60 | CR |
| 23 | HAGA | 27 | PR |
| 24 | HAGA | 36 | CR |
| 25 | HAGA | 55 | CR |
| 26 | HAGA | 58 | PR |
| 27 | HAGA | 55 | PR |
| 28 | HAGA | 30 | NR |
| 29 | HAGA | 31 | NR |
Abbreviations: CR, complete responder, defined as 100% lesion clearance (n = 14); NR, nonresponders, defined as <50% lesion regression (n = 3); PR, partial responder, defined as ≥50% lesion clearance (n = 12).